US FDA puts Genmab's zalutumumab studies on hold
This article was originally published in Scrip
Executive Summary
The US FDA has placed a partial clinical hold on Genmab's clinical trials of its EGFR-targeted anticancer drug zalutumumab (HuMax-EGFr). The agency has also requested new studies. The companies Phase III trials based outside the US are unaffected by the hold.